Drug intelligence / Profile preview

recombinant gelonin

Development stage
Preclinical
Lead developer
University of Texas MD Anderson Cancer Center
Modality
Recombinant Proteins and Enzymes
Administration
Intravenous
01

Overview

Recombinant gelonin (rGel) is a 30 kDa recombinant version of the Type I ribosome-inactivating protein (RIP) originally isolated from the seeds of *Gelonium multiflorum*. As a Type I RIP, it consists of a single polypeptide chain that possesses potent N-glycosidase activity but lacks the cell-binding B-chain found in Type II RIPs like ricin. This structural characteristic renders rGel relatively non-toxic to cells unless it is specifically internalized via a targeting moiety, such as a monoclonal antibody, single-chain Fv fragment, or growth factor. Once inside the cytosol, rGel specifically cleaves a single adenine residue (A4324) from the sarcin/ricin loop of the 28S ribosomal RNA. This action irreversibly inhibits protein synthesis by preventing the binding of elongation factors, ultimately leading to cell death via apoptosis. It is primarily developed as a cytotoxic payload for targeted cancer therapies, including immunotoxins and fusion proteins.

Other names
rGeloninrecombinant gelonin toxin
02

Targets

SRL (28S rRNA sarcin-ricin loop)

Beyond the preview

Go deeper on recombinant gelonin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on recombinant gelonin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call